TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant
Brief Summary: Main objective : Assessing the effect of epoetin beta on Hb rate and the glomerular filtration rate estimated 30 days after kidney transplant.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta (NeoRecormon ®) | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: epoetin beta (NeoRecormon ®); Assigned to Arm(s): A
B: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo (Epoetin delta) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Intervention Type: DRUG; Name: Dynepo (Epoetin delta); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 4
D: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: C-Pulse Implantable Counterpulsation Pump (ICP) Feasibility Study - A Heart Assist System
Brief Summary: The C-Pulse Feasibility Study is evaluating the safety and performance of a new product for the treatment of heart failure. The product is designed to help reduce the symptoms of heart failure and help patients function better with daily activities. The study evaluates multiple measures of heart function and whether the patient's quality of life has been improved since the device implant. The patient will have several visits after the device implant to assess how well they are doing and to monitor any safety concerns.


Options:
A: Arm Label: Revatio (sildenafil); Type: EXPERIMENTAL; Interventions: Drug: Sildenafil | Arm Label: Placebo; Type: OTHER; Interventions: Drug: Sildenafil | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Placebo, Revatio (sildenafil)
B: Arm Label: eplerenone; Type: ACTIVE_COMPARATOR; Interventions: Drug: eplerenone | Arm Label: sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: eplerenone; Assigned to Arm(s): eplerenone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): sugar pill
C: Arm Label: Implantable Counterpulsation Therapy; Type: EXPERIMENTAL; Interventions: Device: C-Pulse™ (Implantable Counterpulsation Therapy) | Intervention Type: DEVICE; Name: C-Pulse™ (Implantable Counterpulsation Therapy); Assigned to Arm(s): Implantable Counterpulsation Therapy
D: Arm Label: Lisinopril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lisinopril | Arm Label: Losartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: Losartan | Intervention Type: DRUG; Name: Losartan; Assigned to Arm(s): Losartan | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): Lisinopril

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Study of Pharos Vitesse Neurovascular Stent System Compared to Best Medical Therapy for the Treatment of Ischemic Disease
Brief Summary: The main objective of this study is to prospectively evaluate the safety, probable benefit, and effectiveness of the PHAROS Vitesse Neurovascular Stent System in a multicenter, randomized clinical trial.

A secondary objective of this study is to evaluate the impact of stenting in the neurovasculature to treat cerebral ischemia on other outcomes such as hospital length of stay, charges, and costs.


Options:
A: Arm Label: Stent Group; Type: EXPERIMENTAL; Interventions: Device: Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel) | Arm Label: Medical Therapy Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin and Clopidogrel (Medical therapy) | Intervention Type: DEVICE; Name: Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel); Assigned to Arm(s): Stent Group | Intervention Type: DRUG; Name: Aspirin and Clopidogrel (Medical therapy); Assigned to Arm(s): Medical Therapy Group
B: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet
C: Arm Label: aggressive medical treatment; Type: N/A; Interventions: Device: intravascular stent therapy | Intervention Type: DEVICE; Name: intravascular stent therapy; Assigned to Arm(s): aggressive medical treatment
D: Arm Label: stenting+medical treatment; Type: EXPERIMENTAL; Interventions: Procedure: Percutaneous transluminal angioplasty and stenting, Drug: Aspirin plus clopidogrel | Arm Label: Aspirin plus clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin plus clopidogrel | Intervention Type: PROCEDURE; Name: Percutaneous transluminal angioplasty and stenting; Assigned to Arm(s): stenting+medical treatment | Intervention Type: DRUG; Name: Aspirin plus clopidogrel; Assigned to Arm(s): Aspirin plus clopidogrel, stenting+medical treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Study of Pharos Vitesse Neurovascular Stent System Compared to Best Medical Therapy for the Treatment of Ischemic Disease
Brief Summary: The main objective of this study is to prospectively evaluate the safety, probable benefit, and effectiveness of the PHAROS Vitesse Neurovascular Stent System in a multicenter, randomized clinical trial.

A secondary objective of this study is to evaluate the impact of stenting in the neurovasculature to treat cerebral ischemia on other outcomes such as hospital length of stay, charges, and costs.


Options:
A: Arm Label: Stent Group; Type: EXPERIMENTAL; Interventions: Device: Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel) | Arm Label: Medical Therapy Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin and Clopidogrel (Medical therapy) | Intervention Type: DEVICE; Name: Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel); Assigned to Arm(s): Stent Group | Intervention Type: DRUG; Name: Aspirin and Clopidogrel (Medical therapy); Assigned to Arm(s): Medical Therapy Group
B: Arm Label: aggressive medical treatment; Type: N/A; Interventions: Device: intravascular stent therapy | Intervention Type: DEVICE; Name: intravascular stent therapy; Assigned to Arm(s): aggressive medical treatment
C: Arm Label: stenting+medical treatment; Type: EXPERIMENTAL; Interventions: Procedure: Percutaneous transluminal angioplasty and stenting, Drug: Aspirin plus clopidogrel | Arm Label: Aspirin plus clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin plus clopidogrel | Intervention Type: PROCEDURE; Name: Percutaneous transluminal angioplasty and stenting; Assigned to Arm(s): stenting+medical treatment | Intervention Type: DRUG; Name: Aspirin plus clopidogrel; Assigned to Arm(s): Aspirin plus clopidogrel, stenting+medical treatment
D: Arm Label: intensive medical management plus stenting; Type: EXPERIMENTAL; Interventions: Device: intracranial angioplasty and stenting | Arm Label: intensive medical management alone; Type: EXPERIMENTAL; Interventions: Other: intensive medical management | Intervention Type: DEVICE; Name: intracranial angioplasty and stenting; Assigned to Arm(s): intensive medical management plus stenting | Intervention Type: OTHER; Name: intensive medical management; Assigned to Arm(s): intensive medical management alone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis?
Brief Summary: Bronchiectasis is a chronic chest condition which causes a persistent cough and frequent chest infections. One of the main forms of treatment is chest physiotherapy. Physiotherapy is thought to improve cough and help clear the airways of sticky sputum. Traditionally, physiotherapy techniques can be awkward, but recently a new device (a simple mouthpiece, called the Acapella device) has been developed to make physiotherapy practise easier. This study aims to assess how helpful regular physiotherapy using a new mouthpiece is in patients with severe bronchiectasis.


Options:
A: Arm Label: HFCWO; Type: EXPERIMENTAL; Interventions: Device: HFCWO - SmartVest | Arm Label: Placebo/Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: HFCWO - SmartVest; Assigned to Arm(s): HFCWO
B: Arm Label: Autogenic drainage; Type: ACTIVE_COMPARATOR; Interventions: Other: Autogenic drainage | Arm Label: Slow expiration with glottis opened in lateral posture; Type: ACTIVE_COMPARATOR; Interventions: Other: Slow expiration with glottis opened in lateral posture | Arm Label: Temporary-Positive Expiratory Pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Temporary-positive expiratory pressure | Intervention Type: OTHER; Name: Autogenic drainage; Assigned to Arm(s): Autogenic drainage | Intervention Type: OTHER; Name: Slow expiration with glottis opened in lateral posture; Assigned to Arm(s): Slow expiration with glottis opened in lateral posture | Intervention Type: OTHER; Name: Temporary-positive expiratory pressure; Assigned to Arm(s): Temporary-Positive Expiratory Pressure
C: Arm Label: Acapella Physiotherapy; Type: EXPERIMENTAL; Interventions: Device: Acapella Physiotherapy | Arm Label: No physiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Acapella Physiotherapy; Assigned to Arm(s): Acapella Physiotherapy
D: Arm Label: Chest Physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Arm Label: Chest Physiotherapy + Exercise Program; Type: EXPERIMENTAL; Interventions: Procedure: Chest Physiotherapy + Exercise Program | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): Chest Physiotherapy | Intervention Type: PROCEDURE; Name: Chest Physiotherapy + Exercise Program; Assigned to Arm(s): Chest Physiotherapy + Exercise Program

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis?
Brief Summary: Bronchiectasis is a chronic chest condition which causes a persistent cough and frequent chest infections. One of the main forms of treatment is chest physiotherapy. Physiotherapy is thought to improve cough and help clear the airways of sticky sputum. Traditionally, physiotherapy techniques can be awkward, but recently a new device (a simple mouthpiece, called the Acapella device) has been developed to make physiotherapy practise easier. This study aims to assess how helpful regular physiotherapy using a new mouthpiece is in patients with severe bronchiectasis.


Options:
A: Arm Label: Chest Physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Arm Label: Chest Physiotherapy + Exercise Program; Type: EXPERIMENTAL; Interventions: Procedure: Chest Physiotherapy + Exercise Program | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): Chest Physiotherapy | Intervention Type: PROCEDURE; Name: Chest Physiotherapy + Exercise Program; Assigned to Arm(s): Chest Physiotherapy + Exercise Program
B: Arm Label: Acapella Physiotherapy; Type: EXPERIMENTAL; Interventions: Device: Acapella Physiotherapy | Arm Label: No physiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Acapella Physiotherapy; Assigned to Arm(s): Acapella Physiotherapy
C: Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pulmonary rehabilitation; Type: EXPERIMENTAL; Interventions: Procedure: Pulmonary rehabilitation | Intervention Type: PROCEDURE; Name: Pulmonary rehabilitation; Assigned to Arm(s): Pulmonary rehabilitation | Intervention Type: PROCEDURE; Name: Pulmonary rehabilitation; Assigned to Arm(s): Pulmonary rehabilitation
D: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis?
Brief Summary: Bronchiectasis is a chronic chest condition which causes a persistent cough and frequent chest infections. One of the main forms of treatment is chest physiotherapy. Physiotherapy is thought to improve cough and help clear the airways of sticky sputum. Traditionally, physiotherapy techniques can be awkward, but recently a new device (a simple mouthpiece, called the Acapella device) has been developed to make physiotherapy practise easier. This study aims to assess how helpful regular physiotherapy using a new mouthpiece is in patients with severe bronchiectasis.


Options:
A: Arm Label: HFCWC with higher pressure/variable frequency settings; Type: ACTIVE_COMPARATOR; Interventions: Device: HFCWC with higher pressure/variable-frequency settings, Device: HFCWC with lower pressure/mid-frequency settings | Arm Label: HFCWC with lower pressure/mid-frequency settings; Type: ACTIVE_COMPARATOR; Interventions: Device: HFCWC with higher pressure/variable-frequency settings, Device: HFCWC with lower pressure/mid-frequency settings | Intervention Type: DEVICE; Name: HFCWC with higher pressure/variable-frequency settings; Assigned to Arm(s): HFCWC with higher pressure/variable frequency settings, HFCWC with lower pressure/mid-frequency settings | Intervention Type: DEVICE; Name: HFCWC with lower pressure/mid-frequency settings; Assigned to Arm(s): HFCWC with higher pressure/variable frequency settings, HFCWC with lower pressure/mid-frequency settings
B: Arm Label: Chest Physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Arm Label: Chest Physiotherapy + Exercise Program; Type: EXPERIMENTAL; Interventions: Procedure: Chest Physiotherapy + Exercise Program | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): Chest Physiotherapy | Intervention Type: PROCEDURE; Name: Chest Physiotherapy + Exercise Program; Assigned to Arm(s): Chest Physiotherapy + Exercise Program
C: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: Acapella Physiotherapy; Type: EXPERIMENTAL; Interventions: Device: Acapella Physiotherapy | Arm Label: No physiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Acapella Physiotherapy; Assigned to Arm(s): Acapella Physiotherapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis?
Brief Summary: Bronchiectasis is a chronic chest condition which causes a persistent cough and frequent chest infections. One of the main forms of treatment is chest physiotherapy. Physiotherapy is thought to improve cough and help clear the airways of sticky sputum. Traditionally, physiotherapy techniques can be awkward, but recently a new device (a simple mouthpiece, called the Acapella device) has been developed to make physiotherapy practise easier. This study aims to assess how helpful regular physiotherapy using a new mouthpiece is in patients with severe bronchiectasis.


Options:
A: Arm Label: Mannitol; Type: EXPERIMENTAL; Interventions: Drug: Inhaled mannitol | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matched control | Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): Mannitol | Intervention Type: DRUG; Name: Matched control; Assigned to Arm(s): Control
B: Arm Label: Azithromycin treatment 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin treatment 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 2
C: Arm Label: Acapella Physiotherapy; Type: EXPERIMENTAL; Interventions: Device: Acapella Physiotherapy | Arm Label: No physiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Acapella Physiotherapy; Assigned to Arm(s): Acapella Physiotherapy
D: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 1-month, Randomized, Double-blind, Placebo-controlled Study of Fenofibrate 145 mg Tablet in Patients With Sleep Apnea Syndrome
Brief Summary: Objectives: to investigate for the potential effect of fenofibrate on symptoms and biological changes associated with sleep apnea syndrome.


Options:
A: Intervention Type: DRUG; Name: acetazolamide; Assigned to Arm(s): N/A
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: donepezil | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: donepezil; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fenofibrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): 2
D: Arm Label: Budesonide; Type: EXPERIMENTAL; Interventions: Drug: Budesonide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS) - Pilot Study
Brief Summary: This study will test the usefulness of the medication metformin in treating people with schizophrenia or schizoaffective disorder who are overweight and also taking antipsychotic medications.


Options:
A: Arm Label: Naltrexone 50mg; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Naltrexone 25mg; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone 25mg, Naltrexone 50mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Olanzapine/standard behavioral weight intervention; Type: EXPERIMENTAL; Interventions: Drug: Olanzapine, Behavioral: Standard behavioral weight intervention | Arm Label: Olanzapine/intense behavioral weight intervention; Type: EXPERIMENTAL; Interventions: Drug: Olanzapine, Behavioral: Intense behavioral weight intervention | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine/intense behavioral weight intervention, Olanzapine/standard behavioral weight intervention | Intervention Type: BEHAVIORAL; Name: Standard behavioral weight intervention; Assigned to Arm(s): Olanzapine/standard behavioral weight intervention | Intervention Type: BEHAVIORAL; Name: Intense behavioral weight intervention; Assigned to Arm(s): Olanzapine/intense behavioral weight intervention
D: Intervention Type: DRUG; Name: quetiapine fumarate; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS) - Pilot Study
Brief Summary: This study will test the usefulness of the medication metformin in treating people with schizophrenia or schizoaffective disorder who are overweight and also taking antipsychotic medications.


Options:
A: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: Liraglutide | Arm Label: Liraglutide placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Liraglutide Placebo | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: Liraglutide Placebo; Assigned to Arm(s): Liraglutide placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betahistine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Betahistine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): 2
D: Arm Label: Naltrexone and Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone, Drug: Bupropion | Arm Label: Placebo Naltrexone and Bupropion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Naltrexone, Drug: Placebo Bupropion | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone and Bupropion | Intervention Type: DRUG; Name: Placebo Naltrexone; Assigned to Arm(s): Placebo Naltrexone and Bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Naltrexone and Bupropion | Intervention Type: DRUG; Name: Placebo Bupropion; Assigned to Arm(s): Placebo Naltrexone and Bupropion

Answer: A